Skip to main content
SpringerLink
Log in

DR4 and DR5

  • Living reference work entry
  • First Online:
Cancer Therapeutic Targets

  • 164 Accesses

Abstract

TRAIL has two intact functional receptors, termed as TRAIL receptors 1 and 2. TRAIL receptor 1 (TRAILR1) is also known as DR4, TNFRSF10A, APO2, TR10A_HUMAN, was identified in 1997 (Pan et al. 1997), and possesses 468 amino acids (accession number U90875). TRAIL receptor 2 (TRAILR2) is also known as TNFRSF10B, DR5, KILLER, TRICK2, was also identified in 1997, and has two isoforms resulting from alternative splicing. TRAILR2a and TRAILR2b are encoded by 412 and 441 amino acids, respectively (accession numbers AF018657 and AF018658) (Screaton et al. 1997; Wu et al. 1997). The extracellular and intracellular domains for TRAILR2 have 58 % and 65 % similarity to TRAILR1 (Screaton et al. 1997).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer. 2006;42(14):2233–40.

    Article  CAS  PubMed  Google Scholar 

  • Duiker EW, de Vries EG, Mahalingam D, et al. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res. 2009;15(6):2048–57.

    Article  CAS  PubMed  Google Scholar 

  • El-Gazzar A, Perco P, Eckelhart E, et al. Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. Mol Cancer Ther. 2010;9(4):1007–18.

    Article  CAS  PubMed  Google Scholar 

  • Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther. 2008;7(2):163–73.

    Article  CAS  PubMed  Google Scholar 

  • Fisher MJ, Virmani AK, Wu L, et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res. 2001;7(6):1688–97.

    CAS  PubMed  Google Scholar 

  • Guan B, Yue P, Clayman GL, Sun SY. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol. 2001;188(1):98–105.

    Article  CAS  PubMed  Google Scholar 

  • Guan B, Yue P, Lotan R, Sun SY. Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene. 2002;21(20):3121–9.

    Article  CAS  PubMed  Google Scholar 

  • Guo Y, Chen C, Zheng Y, et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem. 2005;280(51):41940–52.

    Article  CAS  PubMed  Google Scholar 

  • Horak P, Pils D, Kaider A, et al. Perturbation of the tumor necrosis factor – related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res. 2005;11(24 Pt 1):8585–91.

    Article  CAS  PubMed  Google Scholar 

  • Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001;7(8):954–60.

    Article  CAS  PubMed  Google Scholar 

  • Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008;8(10):782–98.

    Article  CAS  PubMed  Google Scholar 

  • Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem. 2005;280(3):2205–12.

    Article  CAS  PubMed  Google Scholar 

  • Kim YH, Park JW, Lee JY, Kwon TK. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis. 2004;25(10):1813–20.

    Article  PubMed  Google Scholar 

  • Kurbanov BM, Fecker LF, Geilen CC, Sterry W, Eberle J. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene. 2007;26(23):3364–77.

    Article  CAS  PubMed  Google Scholar 

  • Lee SH, Shin MS, Kim HS, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 1999;59(22):5683–6.

    CAS  PubMed  Google Scholar 

  • Lee SH, Shin MS, Kim HS, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. Oncogene. 2001;20(3):399–403.

    Article  CAS  PubMed  Google Scholar 

  • Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev. 2009;35(3):280–8.

    Article  CAS  PubMed  Google Scholar 

  • Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res. 2001;262(2):154–69.

    Article  CAS  PubMed  Google Scholar 

  • Pan G, O’Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276(5309):111–3.

    Article  CAS  PubMed  Google Scholar 

  • Perraud A, Akil H, Nouaille M, et al. Expression of p53 and DR5 in normal and malignant tissues of colorectal cancer: correlation with advanced stages. Oncol Rep. 2011;26(5):1091–7.

    PubMed  Google Scholar 

  • Sanlioglu AD, Korcum AF, Pestereli E, et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69(3):716–23.

    Article  CAS  PubMed  Google Scholar 

  • Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol. 1997;7(9):693–6.

    Article  CAS  PubMed  Google Scholar 

  • Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998;58(8):1593–8.

    CAS  PubMed  Google Scholar 

  • Shetty S, Graham BA, Brown JG, et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol. 2005;25(13):5404–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shin MS, Kim HS, Lee SH, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 2001;61(13):4942–6.

    CAS  PubMed  Google Scholar 

  • Sun SY, Liu X, Zou W, Yue P, Marcus AI, Khuri FR. The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem. 2007;282(26):18800–9.

    Article  CAS  PubMed  Google Scholar 

  • van Geelen CM, Westra JL, de Vries EG, et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol. 2006;24(31):4998–5004.

    Article  PubMed  Google Scholar 

  • Wagner KW, Punnoose EA, Januario T, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 2007;13(9):1070–7.

    Article  CAS  PubMed  Google Scholar 

  • Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell. 2004;5(5):501–12.

    Article  CAS  PubMed  Google Scholar 

  • Wu GS, Burns TF, McDonald 3rd ER, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997;17(2):141–3.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Medical University Vienna, 18-20, Waehzinger Guertel, 1090, Vienna, Austria

    Michael Krainer

  2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA

    Ahmed El-Gazzar

Authors
  1. Michael Krainer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed El-Gazzar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Krainer .

Editor information

Editors and Affiliations

  1. Georgetown University Div. Hematology & Oncology, Washington, District of Columbia, USA

    John L. Marshall

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this entry

Cite this entry

Krainer, M., El-Gazzar, A. (2013). DR4 and DR5. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6613-0_9-2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6613-0_9-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Online ISBN: 978-1-4614-6613-0

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation